Welcome to our dedicated page for HYPERFINE SEC filings (Ticker: HYPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Hyperfine, Inc. (Nasdaq: HYPR), a health technology and medical device company in the electromedical and electrotherapeutic apparatus manufacturing industry. Hyperfine’s filings offer detailed information on its portable, ultra-low-field brain MRI business built around the Swoop® Portable MR Imaging® System and related AI-powered software.
Investors can use Hyperfine’s periodic reports and current reports to understand the company’s financial condition, capital structure, and key business developments. Form 8-K filings, for example, have disclosed quarterly financial results, preliminary unaudited revenue and cash figures, business highlights related to the commercial rollout of the next generation Swoop® system and Optive AI™ software, and information about underwritten public offerings of Class A common stock. One 8-K also documents that Hyperfine regained compliance with Nasdaq’s minimum bid price requirement, providing context on its listing status.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available on this page) typically include more extensive discussions of revenue sources from MRI device sales and service sales, research and development spending, risk factors, and details on regulatory clearances and market access for the Swoop® system. Filings related to securities offerings, such as the underwriting agreement described in an October 16, 2025 Form 8-K, outline terms of equity raises and associated use of proceeds.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information about revenue trends, cash position, and material agreements. Real-time updates from EDGAR ensure that new Hyperfine filings, including Forms 10-K, 10-Q, 8-K, and ownership-related filings such as Form 4 when available, are added promptly. This makes the HYPR SEC filings page a focused resource for analyzing Hyperfine’s regulatory disclosures, capital markets activity, and evolving business around portable brain MRI technology.
HALE BRETT reported acquisition or exercise transactions in this Form 4 filing.
Hyperfine, Inc. reported that its CFO and CAO, Brett Hale, received an equity compensation grant of 330,000 restricted stock units (RSUs) of Class A common stock. The RSUs have no cash purchase price and represent the right to receive one share per unit upon vesting.
The award vests 25% on March 23, 2027, with the remaining RSUs vesting in equal quarterly installments over the following three years, subject to his continued service. After this grant, Hale beneficially owns 605,812 shares of Class A common stock, including these RSUs.
TEISSEYRE THOMAS reported acquisition or exercise transactions in this Form 4 filing.
Hyperfine, Inc. reported that Chief Operating Officer Dr. Thomas Teisseyre received an equity compensation grant of 330,000 shares of Class A Common Stock in the form of restricted stock units (RSUs). These RSUs carry no purchase price and increase his direct holdings to 684,648 shares.
The RSUs vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over the following three years, conditioned on his continued service. This structure is designed to retain the executive and align his incentives with long‑term company performance.
Hyperfine, Inc. reported that President and CEO Maria Sainz received a grant of 750,000 restricted stock units (RSUs) of Class A common stock at no cash cost. Each RSU converts into one share as it vests, serving as stock-based compensation rather than an open-market purchase.
The RSUs vest 25% on March 23, 2027, with the rest vesting in equal quarterly installments over the following three years, conditioned on her continued service. After this award and recent vesting activity, she directly holds 789,586 shares, including 19,586 shares from a 2021 RSU vesting and 20,000 purchased shares.
Hyperfine, Inc. Chief Operating Officer Thomas Teisseyre reported an open-market sale of 24,188 shares of Class A common stock at $1.21 per share. According to the footnote, the sale was made solely to cover tax withholding obligations tied to the vesting of restricted stock units under a “sell to cover” provision. After this transaction, he directly holds 354,648 shares, indicating it is a routine tax-related disposition rather than a discretionary change in his overall ownership stake.
Hyperfine, Inc. CFO and CAO Brett Hale reported an open-market sale of 24,188 shares of Class A common stock at an average price of $1.21 per share. According to the footnote, these shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and Hale now holds 275,812 shares directly.
Hyperfine, Inc. reports on its business as an early-stage health technology company focused on AI-powered, ultra-low-field portable brain MRI. Its flagship Swoop® Portable MR Imaging® System brings bedside brain imaging to hospitals and neurology offices using a 0.064T permanent magnet and Optive AI™ software.
The company targets more than $16 billion in potential U.S. device placements, selling systems with recurring software, service and support agreements. It emphasizes multiple FDA 510(k) clearances, CE Mark, UKCA Mark and Indian approval, a portfolio of 197 issued patents and 160 pending applications, and a strategy spanning U.S. hospitals, neurology offices and international distributors.
Hyperfine highlights significant risks, including a history of net losses, ongoing capital needs, dependence on market adoption, single-source manufacturing for key components, extensive healthcare regulation, cybersecurity and data-privacy exposure, controlled-company governance, and concentrated voting power with founder Jonathan M. Rothberg, Ph.D.
Hyperfine, Inc. entered into a senior secured term loan agreement with Horizon Technology Finance for up to $40.0 million. The company drew $15.0 million at closing, with another $25.0 million available through December 31, 2027 if conditions are met.
The loan bears interest at the prime rate plus 4.25%, with a prime floor of 6.50% and a minimum overall rate of 10.75%, and initially requires 48 months of interest-only payments. Hyperfine paid a $400,000 commitment fee and must make a final payment equal to 5.0% of the aggregate original principal at payoff.
As part of the financing, Hyperfine issued warrants to Horizon for up to 562,500 shares of Class A common stock as Initial Warrants and up to 520,835 shares as Additional Warrants, each with a $1.20 exercise price. The Initial Warrants are immediately exercisable, while the Additional Warrants become exercisable only if further loan tranches are funded. The loan is guaranteed by two wholly owned subsidiaries and secured by substantially all company assets, subject to customary exclusions, and includes standard covenants and events of default.
Hyperfine, Inc. reported strong top-line momentum for the fourth quarter and full year 2025 while continuing to operate at a net loss. Fourth quarter 2025 revenue was $5.29 million, up 128% from $2.32 million a year earlier, with net 16 Swoop® systems sold versus nine in the prior-year quarter. Gross margin improved to 51% from 36%, and the quarterly net loss narrowed to $5.91 million, or $0.06 per share, compared with a $10.39 million loss, or $0.14 per share.
For full year 2025, revenue reached $13.56 million, up 5.2% from 2024, on 38 systems sold versus 48 in 2024, while gross margin rose to 50% from 46%. The annual net loss was $35.57 million, or $0.43 per share, better than the $40.72 million loss, or $0.56 per share, in 2024. Cash and cash equivalents were $35.09 million as of December 31, 2025, and the company highlighted over $20 million in gross proceeds from an October 2025 equity offering and a $40 million senior secured term loan facility signed in March 2026.
Management guided 2026 revenue to approximately $20 to $22 million, implying 55% growth at the midpoint versus 2025, and expects 2026 cash burn of $26 to $28 million, a 10% decline at the midpoint. The company expects its recent financings and initial debt tranche to support a cash runway into 2028 as it drives adoption of its second-generation Swoop® scanner and Optive AI™ software across hospital, neurology office and international markets.
TEISSEYRE THOMAS reported open-market sale transactions in a Form 4 filing for HYPR. The filing lists transactions totaling 821 shares at a weighted average price of $1.11 per share. Following the reported transactions, holdings were 378,836 shares.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 3,568,038 shares of Hyperfine Inc common stock, representing 4.34% of the class as of the reported date. Vanguard reports no sole voting or dispositive power, with all voting and dispositive authority shared.
The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Hyperfine.